Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Calciphylaxis: Pathogenesis, Diagnosis, and Emerging Treatments
Description
The talk reviews calciphylaxis, a small- and medium-vessel vasculopathy that can occur in dialysis patients but also in non-uremic patients, often associated with warfarin. It emphasizes that the disease causes severe pain, retiform purpura, necrosis, and large ulcers, and that early recognition is critical because lesions can progress rapidly and biopsy may delay treatment or worsen disease. Pathogenesis is presented as multifactorial, involving vascular smooth muscle cell transformation into an osteogenic phenotype, endothelial dysfunction, hypercoagulability, inflammation, vitamin K deficiency, and loss of calcification inhibitors such as matrix GLA protein, pyrophosphate, and fetuin A. Diagnosis is primarily clinical, with imaging and biopsy reserved for atypical cases. Treatment is multidisciplinary and includes correcting metabolic abnormalities, intensifying dialysis, avoiding triggers such as warfarin and high-calcium dialysate, managing hyperparathyroidism with cinacalcet, and using sodium thiosulfate early as a common therapy for its antioxidant, vasodilatory, and calcium-chelating effects. Other options include bisphosphonates, anticoagulation when appropriate, vitamin K1 supplementation, hyperbaric oxygen, and in selected cases transplantation. Emerging therapies and the importance of early pain control are highlighted, along with the encouraging message that outcomes are improving and mortality is lower than historically reported.
View moreConclusions
- Calciphylaxis is now understood as a multifactorial vasculopathic disorder driven by calcification, thrombosis, inflammation, and ischemic necrosis rather than a simple calcium-phosphate imbalance.
- Clinical recognition is crucial because classic lesions can progress rapidly, biopsy can delay treatment, and histology is neither fully sensitive nor fully specific.
- Low levels of calcification inhibitors such as matrix GLA protein, pyrophosphate, fetuin A, and vitamin K appear to contribute importantly to disease risk and severity.
- Warfarin use, vitamin K deficiency, uremia, hyperphosphatemia, and inflammatory states all seem to increase calciphylaxis risk by worsening anti-calcification defenses and promoting thrombosis.
- Early treatment should be multi-modal and individualized, combining dialysis optimization, mineral metabolism control, wound care, pain control, and removal of provoking factors.
- Sodium thiosulfate remains a common first-line therapy because it can reduce pain and stabilize lesions quickly, although the evidence for survival benefit is mixed.
- Cinacalcet, vitamin K1 supplementation, bisphosphonates, and anticoagulation may help selected patients by addressing upstream metabolic, calcification, and thrombotic pathways.
- Hyperbaric oxygen therapy and renal transplantation can improve outcomes in appropriate patients, especially when initiated early and when access barriers can be overcome.
- Proximal, truncal, and penile involvement are associated with worse prognosis than isolated distal disease, so lesion distribution is an important prognostic marker.
- Recent cohorts suggest outcomes are improving overall, with lower mortality than historically reported, especially in non-nephrogenic disease and with earlier diagnosis.
- Recurrence appears uncommon, particularly outside nephrogenic disease, and recurrent episodes are often diagnosed faster with better outcomes.
- Future progress will likely depend on better biomarkers, standardized severity measures, and prospective trials of emerging anti-calcification and anti-inflammatory treatments.
- Kramann et al. Nephrol Dial Transplant. 2013 Apr;28(4):856-68.
- Napoleon et al. Scientific Translational Medicine 2025.
- Chertow et al. Nature Medicine 2024.
- Raymond CB et al. Sodium thiosulfate, bisphosphonates, and cinacalcet for calciphylaxis. CANNIT J. 19(4):25-7; 2009.#10.2146/ajhp070546
- Speeckaert MM et al.
- Sewell JD et al.
- Am J Cardiol 2015.
- ClinicalTrials.gov number, NCT02278692.
- Kaesler, Schreiber, Speer, et al. Kidney International, 2022.
- Saritas, Reingart, Kruger, et al. Clinical Kidney Journal, 2022.
- An J et al. Hyperbaric oxygen in the treatment of calciphylaxis: A case series and literature review. Nephrology. Jul 2015;20(7):444-450.#10.1111/nep.12433
- Nordheim E, Hovd M, Dahle DO. Kidney transplantation and hyperbaric oxygen treatment for calciphylaxis. Kidney Int 2025;107:1113.#10.1016/j.kint.2025.03.003
- Xia et al. Journal of the American Academy of Dermatology, 2024.
- Journal of the American Academy of Dermatology article on calciphylaxis outcomes and mortality, 2025.